IL141645A0 - Use of methoxymorpholino doxorubicin for the treatment of a liver tumor - Google Patents
Use of methoxymorpholino doxorubicin for the treatment of a liver tumorInfo
- Publication number
- IL141645A0 IL141645A0 IL14164599A IL14164599A IL141645A0 IL 141645 A0 IL141645 A0 IL 141645A0 IL 14164599 A IL14164599 A IL 14164599A IL 14164599 A IL14164599 A IL 14164599A IL 141645 A0 IL141645 A0 IL 141645A0
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- liver tumor
- methoxymorpholino doxorubicin
- methoxymorpholino
- doxorubicin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9820012.4A GB9820012D0 (en) | 1998-09-14 | 1998-09-14 | Use of an anthracycline derivative for the treatment of a liver tumor |
PCT/EP1999/006298 WO2000015203A2 (en) | 1998-09-14 | 1999-08-27 | Use of methoxymorpholino doxorubicin for the treatment of a liver tumor |
Publications (1)
Publication Number | Publication Date |
---|---|
IL141645A0 true IL141645A0 (en) | 2002-03-10 |
Family
ID=10838847
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14164599A IL141645A0 (en) | 1998-09-14 | 1999-08-27 | Use of methoxymorpholino doxorubicin for the treatment of a liver tumor |
IL141645A IL141645A (en) | 1998-09-14 | 2001-02-26 | Pharmaceutical preparations containing 3'-desamino-3 '- (2-methoxymorpolino) doxorubicin for the treatment of liver tumors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL141645A IL141645A (en) | 1998-09-14 | 2001-02-26 | Pharmaceutical preparations containing 3'-desamino-3 '- (2-methoxymorpolino) doxorubicin for the treatment of liver tumors |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP1112066B1 (ja) |
JP (2) | JP5529360B2 (ja) |
KR (1) | KR100685155B1 (ja) |
CN (1) | CN1168452C (ja) |
AT (1) | ATE245029T1 (ja) |
AU (1) | AU773451B2 (ja) |
BR (1) | BR9913627A (ja) |
CA (1) | CA2343120C (ja) |
CZ (1) | CZ295901B6 (ja) |
DE (1) | DE69909636T2 (ja) |
DK (1) | DK1112066T3 (ja) |
EA (1) | EA004570B1 (ja) |
ES (1) | ES2203175T3 (ja) |
GB (1) | GB9820012D0 (ja) |
HK (1) | HK1050853A1 (ja) |
HU (1) | HU229186B1 (ja) |
ID (1) | ID28035A (ja) |
IL (2) | IL141645A0 (ja) |
MY (1) | MY124247A (ja) |
NO (1) | NO329746B1 (ja) |
NZ (1) | NZ510445A (ja) |
PL (1) | PL198025B1 (ja) |
PT (1) | PT1112066E (ja) |
TW (1) | TWI222868B (ja) |
UA (1) | UA69423C2 (ja) |
WO (1) | WO2000015203A2 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9909925D0 (en) * | 1999-04-29 | 1999-06-30 | Pharmacia & Upjohn Spa | Combined preparations comprising anthracycline derivatives |
WO2004038404A2 (en) * | 2002-10-28 | 2004-05-06 | Pharmacia Italia Spa | Method for optimizing therapeutic efficacy of nemorubicin |
US20060264388A1 (en) * | 2003-02-26 | 2006-11-23 | Olga Valota | Method for treating liver cancer by intrahepatic administration of nemorubicin |
US8940334B2 (en) | 2007-05-11 | 2015-01-27 | Nerviano Medical Sciences S.R.L. | Pharmaceutical composition of an anthracycline |
JP2016124818A (ja) * | 2014-12-26 | 2016-07-11 | 日本化薬株式会社 | 転移性肝癌治療薬及び転移性肝癌の治療方法 |
PL244818B1 (pl) * | 2021-11-03 | 2024-03-11 | Urteste Spolka Z Ograniczona Odpowiedzialnoscia | Związek-marker diagnostyczny raka wątroby, sposób wykrywania aktywności enzymatycznej, sposób diagnozowania raka wątroby, zestaw zawierający taki związek oraz związek do zastosowania medycznego |
-
1998
- 1998-09-14 GB GBGB9820012.4A patent/GB9820012D0/en not_active Ceased
-
1999
- 1999-08-27 KR KR1020017003222A patent/KR100685155B1/ko not_active IP Right Cessation
- 1999-08-27 EA EA200100353A patent/EA004570B1/ru not_active IP Right Cessation
- 1999-08-27 AT AT99944533T patent/ATE245029T1/de active
- 1999-08-27 IL IL14164599A patent/IL141645A0/xx active IP Right Grant
- 1999-08-27 DK DK99944533T patent/DK1112066T3/da active
- 1999-08-27 HU HU0103557A patent/HU229186B1/hu not_active IP Right Cessation
- 1999-08-27 CN CNB998109118A patent/CN1168452C/zh not_active Expired - Fee Related
- 1999-08-27 PL PL348749A patent/PL198025B1/pl unknown
- 1999-08-27 JP JP2000569787A patent/JP5529360B2/ja not_active Expired - Fee Related
- 1999-08-27 CZ CZ2001895A patent/CZ295901B6/cs not_active IP Right Cessation
- 1999-08-27 CA CA002343120A patent/CA2343120C/en not_active Expired - Fee Related
- 1999-08-27 WO PCT/EP1999/006298 patent/WO2000015203A2/en active IP Right Grant
- 1999-08-27 PT PT99944533T patent/PT1112066E/pt unknown
- 1999-08-27 BR BR9913627-9A patent/BR9913627A/pt not_active Application Discontinuation
- 1999-08-27 ID IDW20010805A patent/ID28035A/id unknown
- 1999-08-27 AU AU57421/99A patent/AU773451B2/en not_active Ceased
- 1999-08-27 NZ NZ510445A patent/NZ510445A/xx not_active IP Right Cessation
- 1999-08-27 UA UA2001042524A patent/UA69423C2/uk unknown
- 1999-08-27 DE DE69909636T patent/DE69909636T2/de not_active Expired - Lifetime
- 1999-08-27 ES ES99944533T patent/ES2203175T3/es not_active Expired - Lifetime
- 1999-08-27 EP EP99944533A patent/EP1112066B1/en not_active Expired - Lifetime
- 1999-09-03 TW TW088115180A patent/TWI222868B/zh not_active IP Right Cessation
- 1999-09-10 MY MYPI99003920A patent/MY124247A/en unknown
-
2001
- 2001-02-26 IL IL141645A patent/IL141645A/en not_active IP Right Cessation
- 2001-03-05 NO NO20011116A patent/NO329746B1/no not_active IP Right Cessation
-
2003
- 2003-05-02 HK HK03103135A patent/HK1050853A1/xx not_active IP Right Cessation
-
2013
- 2013-12-10 JP JP2013255003A patent/JP2014088398A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA02010801A (es) | Agentes diagnosticos, de representacion y terapeuticos cationicos asociados con sitios vasculares activados. | |
SG160412A1 (en) | Anti-igfr1 antibody therapeutic combinations | |
WO2002046477A3 (en) | Endogenous retroviruses up-regulated in prostate cancer | |
EA200100111A1 (ru) | Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами | |
UA87877C2 (en) | Pegylated liposomal doxorubicin in combination with ecteinescidin 743 | |
EP0954340A4 (en) | ASSOCIATED TARGET IMMUNOTHERAPY AGAINST CANCER | |
AU2001249549A1 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
WO2003072754A3 (en) | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use | |
WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
MY137766A (en) | Exemestane as chemopreventing agent | |
WO2000066093A3 (en) | Combined preparations comprising morpholine anthracyclines and anticancer agent | |
WO2000013712A3 (en) | Methods and compositions for the prevention or treatment of cancer | |
IL141645A0 (en) | Use of methoxymorpholino doxorubicin for the treatment of a liver tumor | |
DE602005026510D1 (en) | Anthracyclinderivate | |
EP1234585A3 (en) | Methods and compositions for the prevention or treatment of cancer | |
CO5170459A1 (es) | Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed |